While direct GPR81 antagonists remain in preclinical development, their ability to reverse lactate-driven immunosuppression in breast and other tumor models reinforces the therapeutic value of targeting lactate signaling pathways [49]. This evidence concerns the gene HCAR1 and neoplasm.